MA46901A - Agents psychotropes et leurs utilisations - Google Patents

Agents psychotropes et leurs utilisations

Info

Publication number
MA46901A
MA46901A MA046901A MA46901A MA46901A MA 46901 A MA46901 A MA 46901A MA 046901 A MA046901 A MA 046901A MA 46901 A MA46901 A MA 46901A MA 46901 A MA46901 A MA 46901A
Authority
MA
Morocco
Prior art keywords
psychotropic agents
psychotropic
agents
Prior art date
Application number
MA046901A
Other languages
English (en)
Inventor
Vincent T Grattan
Zachary Prensky
Andrew R Vaino
Original Assignee
Lb Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lb Pharmaceuticals Inc filed Critical Lb Pharmaceuticals Inc
Publication of MA46901A publication Critical patent/MA46901A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA046901A 2016-11-28 2017-11-28 Agents psychotropes et leurs utilisations MA46901A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427062P 2016-11-28 2016-11-28
US201762508263P 2017-05-18 2017-05-18

Publications (1)

Publication Number Publication Date
MA46901A true MA46901A (fr) 2019-10-02

Family

ID=62195369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046901A MA46901A (fr) 2016-11-28 2017-11-28 Agents psychotropes et leurs utilisations

Country Status (11)

Country Link
US (8) US10259786B2 (fr)
EP (1) EP3544606B1 (fr)
JP (1) JP6968899B2 (fr)
KR (1) KR102274338B1 (fr)
CN (2) CN110248655B (fr)
AU (2) AU2017364899B2 (fr)
BR (1) BR112019010127A2 (fr)
ES (1) ES2908949T3 (fr)
MA (1) MA46901A (fr)
SG (1) SG10201914135TA (fr)
WO (1) WO2018098497A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017364899B2 (en) * 2016-11-28 2023-07-06 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
US11377421B2 (en) * 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
CN110944630A (zh) * 2017-05-18 2020-03-31 Lb制药公司 精神药剂及其用途
CN110790693A (zh) * 2018-08-02 2020-02-14 北京万全德众医药生物技术有限公司 一种(s)(-)-氨磺必利的制备方法
CA3217877A1 (fr) * 2021-05-18 2022-11-24 Lb Pharmaceuticals Inc. Agents psychotropes et leurs utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US4210660A (en) 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
US4772630A (en) * 1984-11-23 1988-09-20 Ciba-Geigy Corp. Benzamides and their salts
FR2678266A1 (fr) * 1991-06-28 1992-12-31 Delagrange Laboratoires Nouveaux derives de 2-hydroxy 4-amino 5-ethylsulfonyl benzamide utiles comme anxiolytiques.
CN1147248A (zh) * 1994-04-28 1997-04-09 山之内制药株式会社 N-(3-吡咯烷基)苯甲酰胺衍生物
US5606482A (en) * 1995-04-14 1997-02-25 Lucent Technologies Inc. Solid state circuit breaker
FR2753376B1 (fr) 1996-09-18 1998-10-16 Synthelabo Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2010507648A (ja) 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸nmda活性を有する新規向精神薬
US20080108602A1 (en) 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US20100105755A1 (en) 2008-09-12 2010-04-29 Auspex Pharmaceuticals, Inc. Substituted benzamide modulators of dopamine receptor
WO2012062697A1 (fr) 2010-11-08 2012-05-18 Novartis Ag Polythérapie pour diabète de type 1
EP2755651A1 (fr) * 2011-09-13 2014-07-23 Biomed Valley Discoveries, Inc. Compositions et méthodes pour le traitement des troubles métaboliques
CN102807516A (zh) 2012-08-16 2012-12-05 四川省百草生物药业有限公司 氨磺必利的中间体及利用该中间体制备氨磺必利的方法
JP2019502729A (ja) 2016-01-22 2019-01-31 ダウ アグロサイエンシィズ エルエルシー 4−アルコキシ−3−ヒドロキシピコリン酸を製造する方法
AU2017364899B2 (en) 2016-11-28 2023-07-06 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
CN110944630A (zh) 2017-05-18 2020-03-31 Lb制药公司 精神药剂及其用途
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도

Also Published As

Publication number Publication date
SG10201914135TA (en) 2020-02-27
US10259786B2 (en) 2019-04-16
US12060327B2 (en) 2024-08-13
US20200079734A1 (en) 2020-03-12
US20180170868A1 (en) 2018-06-21
US20240150283A1 (en) 2024-05-09
EP3544606B1 (fr) 2022-03-09
US11040943B2 (en) 2021-06-22
EP3544606A1 (fr) 2019-10-02
KR102274338B1 (ko) 2021-07-06
US10689338B2 (en) 2020-06-23
BR112019010127A2 (pt) 2019-08-20
US20200055818A1 (en) 2020-02-20
US20240158347A1 (en) 2024-05-16
US20180155282A1 (en) 2018-06-07
AU2017364899A1 (en) 2019-05-30
US20200002277A1 (en) 2020-01-02
EP3544606A4 (fr) 2019-12-18
CN110248655B (zh) 2023-07-07
US20220144770A1 (en) 2022-05-12
CN110248655A (zh) 2019-09-17
CN111233731B (zh) 2021-05-14
ES2908949T3 (es) 2022-05-04
KR20190086536A (ko) 2019-07-22
AU2023241329A1 (en) 2023-10-26
US10167256B2 (en) 2019-01-01
CN111233731A (zh) 2020-06-05
US11713295B2 (en) 2023-08-01
WO2018098497A1 (fr) 2018-05-31
JP2019535837A (ja) 2019-12-12
JP6968899B2 (ja) 2021-11-17
AU2017364899B2 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA56480A (fr) Agonistes du récepteur glp-1 et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA50502A (fr) Adénovirus et utilisations associées
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
MA43529A (fr) Modulateurs de transport nucléaire et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA43205A (fr) Composés pyy sélectifs et leurs utilisations